Stock Market Reviews

TWST (Twist Bioscience Corporation) News

Get the latest news, insights, and market updates on TWST (Twist Bioscience Corporation). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Twist Bioscience to Present at Upcoming Investor Conferences
  SOUTH SAN FRANCISCO, Calif., February 18, 2026--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience, will participate in fireside chats at the following upcoming investor conferences.
  Feb 18, 2026 - $TWST
• Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement
  SOUTH SAN FRANCISCO, Calif., February 17, 2026--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it has entered into a licensing agreement with Invenra Inc. ("Invenra"), a company that has developed platform technologies to discover therapeutic antibody candidates. Under the terms of the agreement, Twist will become the co-exclusive provider, together with Invenra, of Invenra’s B-Body® bispecific antibody platform ("B-Body platform"),
  Feb 17, 2026 - $TWST
• Biotech Beat Nvidia in 2025. Can It Do It Again?
  Big pharma and biotech take the earnings stage with reports from Eli Lilly and Novo Nordisk leading the lineup. Will they help the industry once again outperform AI champ Nvidia?
  Feb 11, 2026 - $TWST
• Twist Bioscience Launches Next-Generation Library Preparation Kits Powered by Proprietary Enzymes
  SOUTH SAN FRANCISCO, Calif., February 10, 2026--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched the Twist TrueAmp Library Preparation Kit and Twist PCR-Free WGS Library Preparation Kit, each designed to address a wide range of sample input, including low input and challenging sample types, to enable clinical research.
  Feb 10, 2026 - $TWST
• Twist Bioscience Annual Meeting: Shareholders Elect Directors, Approve Pay and EY Auditor Ratification
  Twist Bioscience (NASDAQ:TWST) held its 2026 annual meeting of stockholders via an online webcast, with Lead Independent Director Robert Chess serving as chairman. The meeting focused on three standard items of corporate governance: electing directors, conducting a non-binding advisory vote on execu
  Feb 9, 2026 - $TWST
• Twist Bioscience Guidance Lift Puts AI Demand And Risks In Focus
  Twist Bioscience (NasdaqGS:TWST) raised its full year revenue guidance, reflecting updated expectations for its business in synthetic DNA and protein solutions. The company highlighted strong demand for its AI enabled DNA and protein platforms, supported by expanding collaborations across discovery and research. Twist Bioscience also announced significant inducement equity awards tied to recent hires, aimed at supporting ongoing growth initiatives. Twist Bioscience, trading at $48.12, has...
  Feb 5, 2026 - $TWST
• Assessing Twist Bioscience (TWST) Valuation After Recent Share Price Momentum
  What recent performance says about Twist Bioscience (TWST) Twist Bioscience (TWST) has attracted fresh attention after a sharp move in its share price, with the stock showing double digit gains over the past month and over the past three months. At a last close of US$46.32, the company now has a three-year total return of 76.9%, alongside a 12-month total return of an 11% decline and a five-year total return of a 74.2% decline. See our latest analysis for Twist Bioscience. The recent 43%...
  Feb 4, 2026 - $TWST
• Twist Bioscience Corporation (TWST): A Bull Case Theory
  We came across a bullish thesis on Twist Bioscience Corporation on Clinical Catalysts’s Substack. In this article, we will summarize the bulls’ thesis on TWST. Twist Bioscience Corporation’s share was trading at $41.58 as of January 29th. Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. TWST has built a differentiated position through its silicon-based DNA synthesis technology, which enables […]
  Feb 3, 2026 - $TWST
• Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
  SOUTH SAN FRANCISCO, Calif., February 03, 2026--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) ("Twist" or the "Company"), a mid-cap growth and value biotech company, today announced that a total of 114,869 equity awards, consisting of 107,742 restricted stock units ("RSUs") and up to 7,127 performance stock units ("PSUs"), will be granted to 52 recently hired individuals, in each case as an inducement material to their acceptance of employment w
  Feb 3, 2026 - $TWST
• Twist Bioscience Q1 Earnings Call Highlights
  Twist Bioscience (NASDAQ:TWST) reported fiscal 2026 first-quarter results that management said extended a multi-year trend of consistent execution, highlighting its 12th consecutive quarter of revenue growth and continued progress toward profitability. On the company’s earnings call, executives emph
  Feb 2, 2026 - $TWST